Does the media prefer MYGN or RNTX?

In the previous week, Myriad Genetics had 5 more articles in the media than Rein Therapeutics. MarketBeat recorded 8 mentions for Myriad Genetics and 3 mentions for Rein Therapeutics. Rein Therapeutics' average media sentiment score of 1.61 beat Myriad Genetics' score of 0.64 indicating that Rein Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Myriad Genetics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rein Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger valuation and earnings, GALT or RNTX?

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galectin Therapeutics N/A N/A -$30.84M -$0.43 N/A Rein Therapeutics N/A N/A -$49.87M -$1.72 N/A

Is GALT or RNTX more profitable?

Company Net Margins Return on Equity Return on Assets Galectin Therapeutics N/A N/A -176.83% Rein Therapeutics N/A N/A -63.69%

Does the media favor GALT or RNTX?

In the previous week, Galectin Therapeutics had 1 more articles in the media than Rein Therapeutics. MarketBeat recorded 4 mentions for Galectin Therapeutics and 3 mentions for Rein Therapeutics. Rein Therapeutics' average media sentiment score of 1.61 beat Galectin Therapeutics' score of 0.80 indicating that Rein Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galectin Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rein Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger earnings and valuation, IRON or RNTX?

Disc Medicine is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Disc Medicine N/A N/A -$212.18M -$6.58 N/A Rein Therapeutics N/A N/A -$49.87M -$1.72 N/A

Is IRON or RNTX more profitable?

Rein Therapeutics' return on equity of 0.00% beat Disc Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Disc Medicine N/A -37.17% -33.65% Rein Therapeutics N/A N/A -63.69%

Does the media prefer IRON or RNTX?

In the previous week, Disc Medicine had 17 more articles in the media than Rein Therapeutics. MarketBeat recorded 20 mentions for Disc Medicine and 3 mentions for Rein Therapeutics. Rein Therapeutics' average media sentiment score of 1.61 beat Disc Medicine's score of 0.60 indicating that Rein Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 7 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Rein Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to RNTX or BCYC?

In the previous week, Rein Therapeutics had 1 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 3 mentions for Rein Therapeutics and 2 mentions for Bicycle Therapeutics. Rein Therapeutics' average media sentiment score of 1.61 beat Bicycle Therapeutics' score of 0.94 indicating that Rein Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rein Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Bicycle Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor FATE or RNTX?

In the previous week, Fate Therapeutics had 1 more articles in the media than Rein Therapeutics. MarketBeat recorded 4 mentions for Fate Therapeutics and 3 mentions for Rein Therapeutics. Rein Therapeutics' average media sentiment score of 1.61 beat Fate Therapeutics' score of 0.94 indicating that Rein Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fate Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rein Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Rein Therapeutics (RNTX) Competitors

$0.78 +0.00 (+0.53%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$0.80 +0.02 (+2.42%)

As of 09/11/2026 06:33 PM Eastern

Compare

RNTX vs. MYGN, GALT, IRON, BCYC, and FATE

Should you buy Rein Therapeutics stock or one of its competitors? Rein Therapeutics's main competitors and comparable companies include Myriad Genetics (MYGN), Galectin Therapeutics (GALT), Disc Medicine (IRON), Bicycle Therapeutics (BCYC), and Fate Therapeutics (FATE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Rein Therapeutics compare to Myriad Genetics?

Myriad Genetics (NASDAQ:MYGN) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

Myriad Genetics currently has a consensus target price of $3.12, suggesting a potential downside of 8.77%. Rein Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 664.33%. Given Rein Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Rein Therapeutics is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Myriad Genetics	3 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.57
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Myriad Genetics had 5 more articles in the media than Rein Therapeutics. MarketBeat recorded 8 mentions for Myriad Genetics and 3 mentions for Rein Therapeutics. Rein Therapeutics' average media sentiment score of 1.61 beat Myriad Genetics' score of 0.64 indicating that Rein Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Myriad Genetics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rein Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Myriad Genetics has a beta of 1.68, indicating that its stock price is 68% more volatile than the broader market. Comparatively, Rein Therapeutics has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market.

Rein Therapeutics has a net margin of 0.00% compared to Myriad Genetics' net margin of -13.96%. Rein Therapeutics' return on equity of 0.00% beat Myriad Genetics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Myriad Genetics	-13.96%	-16.09%	-8.10%
Rein Therapeutics	N/A	N/A	-63.69%

Rein Therapeutics has lower revenue, but higher earnings than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Myriad Genetics	$824.50M	0.40	-$365.90M	-$1.19	N/A
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.72	N/A

99.0% of Myriad Genetics shares are held by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are held by institutional investors. 1.9% of Myriad Genetics shares are held by insiders. Comparatively, 1.5% of Rein Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Rein Therapeutics beats Myriad Genetics on 8 of the 15 factors compared between the two stocks.

How does Rein Therapeutics compare to Galectin Therapeutics?

Galectin Therapeutics (NASDAQ:GALT) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

In the previous week, Galectin Therapeutics had 1 more articles in the media than Rein Therapeutics. MarketBeat recorded 4 mentions for Galectin Therapeutics and 3 mentions for Rein Therapeutics. Rein Therapeutics' average media sentiment score of 1.61 beat Galectin Therapeutics' score of 0.80 indicating that Rein Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galectin Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rein Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-176.83%
Rein Therapeutics	N/A	N/A	-63.69%

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.43	N/A
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.72	N/A

Galectin Therapeutics currently has a consensus target price of $11.00, suggesting a potential upside of 181.33%. Rein Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 664.33%. Given Rein Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Rein Therapeutics is more favorable than Galectin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Galectin Therapeutics has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Rein Therapeutics has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market.

11.7% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are owned by institutional investors. 52.6% of Galectin Therapeutics shares are owned by insiders. Comparatively, 1.5% of Rein Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Rein Therapeutics beats Galectin Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Rein Therapeutics compare to Disc Medicine?

Disc Medicine (NASDAQ:IRON) and Rein Therapeutics (NASDAQ:RNTX) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

In the previous week, Disc Medicine had 17 more articles in the media than Rein Therapeutics. MarketBeat recorded 20 mentions for Disc Medicine and 3 mentions for Rein Therapeutics. Rein Therapeutics' average media sentiment score of 1.61 beat Disc Medicine's score of 0.60 indicating that Rein Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Disc Medicine	7 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Rein Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Disc Medicine presently has a consensus target price of $109.55, suggesting a potential upside of 56.36%. Rein Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 664.33%. Given Rein Therapeutics' higher probable upside, analysts plainly believe Rein Therapeutics is more favorable than Disc Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Rein Therapeutics' return on equity of 0.00% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Disc Medicine	N/A	-37.17%	-33.65%
Rein Therapeutics	N/A	N/A	-63.69%

Disc Medicine has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Rein Therapeutics has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market.

83.7% of Disc Medicine shares are held by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are held by institutional investors. 3.8% of Disc Medicine shares are held by company insiders. Comparatively, 1.5% of Rein Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Disc Medicine is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Disc Medicine	N/A	N/A	-$212.18M	-$6.58	N/A
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.72	N/A

Summary

Rein Therapeutics beats Disc Medicine on 8 of the 13 factors compared between the two stocks.

How does Rein Therapeutics compare to Bicycle Therapeutics?

Rein Therapeutics (NASDAQ:RNTX) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

Rein Therapeutics has higher earnings, but lower revenue than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.72	N/A
Bicycle Therapeutics	$72.86M	3.71	-$218.96M	-$2.73	N/A

90.9% of Rein Therapeutics shares are owned by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are owned by institutional investors. 1.5% of Rein Therapeutics shares are owned by company insiders. Comparatively, 22.0% of Bicycle Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Rein Therapeutics currently has a consensus price target of $6.00, indicating a potential upside of 664.33%. Bicycle Therapeutics has a consensus price target of $13.86, indicating a potential upside of 258.99%. Given Rein Therapeutics' higher probable upside, research analysts clearly believe Rein Therapeutics is more favorable than Bicycle Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

Rein Therapeutics has a beta of 1.37, meaning that its share price is 37% more volatile than the broader market. Comparatively, Bicycle Therapeutics has a beta of 1.54, meaning that its share price is 54% more volatile than the broader market.

In the previous week, Rein Therapeutics had 1 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 3 mentions for Rein Therapeutics and 2 mentions for Bicycle Therapeutics. Rein Therapeutics' average media sentiment score of 1.61 beat Bicycle Therapeutics' score of 0.94 indicating that Rein Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rein Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Bicycle Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rein Therapeutics has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -311.11%. Rein Therapeutics' return on equity of 0.00% beat Bicycle Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rein Therapeutics	N/A	N/A	-63.69%
Bicycle Therapeutics	-311.11%	-33.22%	-27.79%

Summary

Rein Therapeutics beats Bicycle Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Rein Therapeutics compare to Fate Therapeutics?

Fate Therapeutics (NASDAQ:FATE) and Rein Therapeutics (NASDAQ:RNTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 90.9% of Rein Therapeutics shares are held by institutional investors. 4.7% of Fate Therapeutics shares are held by company insiders. Comparatively, 1.5% of Rein Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Fate Therapeutics had 1 more articles in the media than Rein Therapeutics. MarketBeat recorded 4 mentions for Fate Therapeutics and 3 mentions for Rein Therapeutics. Rein Therapeutics' average media sentiment score of 1.61 beat Fate Therapeutics' score of 0.94 indicating that Rein Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fate Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rein Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Fate Therapeutics has a beta of 2.54, suggesting that its stock price is 154% more volatile than the broader market. Comparatively, Rein Therapeutics has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market.

Fate Therapeutics presently has a consensus target price of $5.90, suggesting a potential upside of 155.41%. Rein Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 664.33%. Given Rein Therapeutics' higher possible upside, analysts clearly believe Rein Therapeutics is more favorable than Fate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fate Therapeutics	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Rein Therapeutics has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,941.09%. Rein Therapeutics' return on equity of 0.00% beat Fate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fate Therapeutics	-1,941.09%	-65.08%	-41.73%
Rein Therapeutics	N/A	N/A	-63.69%

Rein Therapeutics has lower revenue, but higher earnings than Fate Therapeutics. Fate Therapeutics is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fate Therapeutics	$6.65M	41.62	-$136.32M	-$1.05	N/A
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.72	N/A

Summary

Fate Therapeutics beats Rein Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Rein Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RNTX vs. The Competition

Export

Metric	Rein Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$67.72M	$3.85B	$7.15B	$12.85B
Dividend Yield	N/A	3.65%	2.57%	11.17%
P/E Ratio	-0.46	14.18	274.94	25.36
Price / Sales	N/A	1,374.99	686.57	116.78
Price / Cash	13.73	106.50	76.65	51.52
Price / Book	-0.73	15.12	10.33	6.20
Net Income	-$49.87M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-11.71%	-4.34%	-3.32%	-2.35%
1 Month Performance	-0.32%	0.54%	-0.53%	-3.23%
1 Year Performance	-34.03%	40.74%	23.51%	8.79%

Rein Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RNTX Rein Therapeutics	3.4426 of 5 stars	$0.79 +0.5%	$6.00 +664.3%	-34.0%	$67.72M	N/A	N/A	9	Positive News Gap Up
MYGN Myriad Genetics	1.0799 of 5 stars	$3.19 flat	$3.60 +12.9%	-52.8%	$305.12M	$824.50M	N/A	2,700	Analyst Forecast
GALT Galectin Therapeutics	1.9524 of 5 stars	$4.61 flat	$11.00 +138.6%	-27.2%	$303.62M	N/A	N/A	9	News Coverage Positive News
IRON Disc Medicine	2.2054 of 5 stars	$79.23 flat	$107.70 +35.9%	+17.1%	$303.45M	N/A	N/A	30	News Coverage Analyst Forecast Insider Trade
BCYC Bicycle Therapeutics	2.3239 of 5 stars	$4.30 flat	$13.86 +222.3%	-45.4%	$300.96M	$72.86M	N/A	240	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RNTX) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rein Therapeutics (RNTX) Competitors

RNTX vs. MYGN, GALT, IRON, BCYC, and FATE

How does Rein Therapeutics compare to Myriad Genetics?

Summary

How does Rein Therapeutics compare to Galectin Therapeutics?

Summary

How does Rein Therapeutics compare to Disc Medicine?

Summary

How does Rein Therapeutics compare to Bicycle Therapeutics?

Summary

How does Rein Therapeutics compare to Fate Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNTX vs. The Competition

Rein Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rein Therapeutics (RNTX) Competitors

RNTX vs. MYGN, GALT, IRON, BCYC, and FATE

How does Rein Therapeutics compare to Myriad Genetics?

Do analysts recommend MYGN or RNTX?

Does the media prefer MYGN or RNTX?

Which has more volatility & risk, MYGN or RNTX?

Is MYGN or RNTX more profitable?

Which has higher valuation and earnings, MYGN or RNTX?

Do institutionals & insiders have more ownership in MYGN or RNTX?

Summary

How does Rein Therapeutics compare to Galectin Therapeutics?

Does the media favor GALT or RNTX?

Is GALT or RNTX more profitable?

Which has stronger valuation and earnings, GALT or RNTX?

Do analysts prefer GALT or RNTX?

Which has more risk & volatility, GALT or RNTX?

Do insiders & institutionals hold more shares of GALT or RNTX?

Summary

How does Rein Therapeutics compare to Disc Medicine?

Does the media prefer IRON or RNTX?

Do analysts recommend IRON or RNTX?

Is IRON or RNTX more profitable?

Which has more risk & volatility, IRON or RNTX?

Do insiders and institutionals hold more shares of IRON or RNTX?

Which has stronger earnings and valuation, IRON or RNTX?

Summary

How does Rein Therapeutics compare to Bicycle Therapeutics?

Which has preferable earnings and valuation, RNTX or BCYC?

Do insiders & institutionals have more ownership in RNTX or BCYC?

Do analysts recommend RNTX or BCYC?

Which has more risk and volatility, RNTX or BCYC?

Does the media refer more to RNTX or BCYC?

Is RNTX or BCYC more profitable?

Summary

How does Rein Therapeutics compare to Fate Therapeutics?

Do institutionals and insiders hold more shares of FATE or RNTX?

Does the media favor FATE or RNTX?

Which has more volatility and risk, FATE or RNTX?

Do analysts recommend FATE or RNTX?

Is FATE or RNTX more profitable?

Which has higher earnings & valuation, FATE or RNTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNTX vs. The Competition

Rein Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools